Ignite Creation Date:
2024-05-06 @ 2:17 AM
Last Modification Date:
2024-10-26 @ 11:16 AM
Study NCT ID:
NCT02016833
Status:
COMPLETED
Last Update Posted:
2015-04-30
First Post:
2013-12-05
Brief Title:
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
Sponsor:
PX Biosolutions
Organization:
PX Biosolutions
Study Overview
Official Title:
Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1 Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1 Survivin and HPV16 E7-specific immune responses in cancer patients Such a study will allow the development of suitable immunological tools to be used in assessing response in a subsequent phase I study aiming at evaluating therapeutic vaccine candidates targeting WT-1 Survivin andor HPV16 E7-expressing tumors In addition this study will help defining the baseline cancer-associated immune responses in the selected patient population
Cervical and ovarian cancer patients as well as leukemia patients will be included in this study
WT-1 Survivin and HPV-specific immune responses will be monitored in these patients by ex vivo and cultured IFNg ELISpot as well as tetramer staining
Cervical and ovarian cancer patients as well as leukemia patients will be included in this study
WT-1 Survivin and HPV-specific immune responses will be monitored in these patients by ex vivo and cultured IFNg ELISpot as well as tetramer staining
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None